|
|
News Breaks | | | | March 4, 2013 | | 08:42 EDT |  | SRPT | Sarepta announces positive resluts from study of AVI-7288
Sarepta announced positive results from a non-human primate study of AVI-7288, the company's lead drug candidate for the treatment of Marburg virus infection. The data showed that intramuscular administration of AVI-7288 resulted in survival rates up to 100 percent in treated subjects, similar to efficacy observed in previous studies that evaluated the drug when administered by intravenous injection. Marburg hemorrhagic fever is a severe and highly lethal disease with no effective treatments, and it has been classified as a Category A bioterrorism agent by the Centers for Disease Control and Prevention. In the study, intramuscular injections of AVI-7288 were well tolerated. Efficacy results showed a high degree of survival between 83 and 100 percent in each of the three treatment groups. No subjects survived in the placebo-treated control group. Under a separate contract with JPM-TMT, Sarepta is developing an intravenous formulation of AVI-7288, which has demonstrated similar survival rates even when the drug is administered up to four days after exposure to the Marburg virus. | |
|
News For SRPT From The Last 14 Days Check below for free stories on SRPT the last two weeks. |
|
|
| May 21, 2013 | | 07:34 EDT |  | SRPT | UBS to host a conference
 Subscribe for More Information | | | May 16, 2013 | | 07:29 EDT | | SRPT | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. | |
|
|
|
|
|
|
